Disproportionality analysis of satralizumab in FDA adverse event reporting system and Japanese adverse drug event report: a pharmacovigilance study
The adverse risks associated with satralizumab are notable. Our findings provide evidence to support risk assessment in clinical practice; however, high-quality clinical studies are still needed to validate these results and to further explore the long-term safety and efficacy of the drug.
Authors
- Rong Yan (ORCID: https://orcid.org/0000-0002-8183-4212)
- Linhai Zhang (ORCID: https://orcid.org/0000-0003-1009-6870)
- Zucai Xu
Institutions
- Zunyi Medical University (CN)
- VIB-KU Leuven Center for Brain & Disease Research (BE)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-01-14
- DOI
- https://doi.org/10.3389/fimmu.2025.1647306
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- U.S. Food and Drug Administration